Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruiting
NCT07405801Phase 2Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Brazil, Canada, France +7 more
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruiting
NCT06624085Phase 1Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Lymphoma
United States, Puerto Rico
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruiting
NCT07347600N/AUpdated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Locally Advanced Breast Cancer · Metastatic Breast Cancer
China
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruiting
NCT05091424Phase 1Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
United States, Australia, China, France, Germany +5 more
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07158242Phase 3Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
United States, Australia, Brazil, Canada, China +4 more
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruiting
NCT06862869N/AUpdated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
China
A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart DiseaseActive Not Recruiting
NCT07495813Phase 1Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Stable Coronary Artery Disease · Healthy Volunteers
Netherlands
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruiting
NCT07200375N/AUpdated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
China, Hong Kong
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT07298421Phase 3Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
United States, Australia, Brazil, Mexico, South Africa +3 more
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive Not Recruiting
NCT04589845Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Australia, Belgium, Brazil, Canada +18 more
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Active Not Recruiting
NCT06450639Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Duchenne Muscular Dystrophy
United States, Denmark, Italy, Poland, Spain +1 more
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic DermatitisRecruiting
NCT07223697Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Atopic Dermatitis
United States, Brazil, Canada, Germany, Italy +2 more
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruiting
NCT07368998Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Belgium, Mexico +3 more
A Study to Investigate Mechanisms of Resistance to Breast Cancer TherapiesRecruiting
NCT06274515Phase 4Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
Belgium, Denmark, Finland, Germany, Italy +3 more
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseActive Not Recruiting
NCT05271409Phase 3Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
United States, Australia, Brazil, Canada, France +6 more
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseActive Not Recruiting
NCT04777331Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Parkinsons Disease
United States, Austria, Canada, France, Italy +4 more
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruiting
NCT07416604Phase 3Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Hemophilia A
United States, Argentina, Belgium, Brazil, China +14 more
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)Recruiting
NCT07416552Phase 1Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Metastatic Colorectal Cancer
United States
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active Not Recruiting
NCT04586023Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Austria, Brazil, Bulgaria, Canada +12 more
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active Not Recruiting
NCT03178552Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +22 more
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyRecruiting
NCT05861986Phase 4Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Muscular Atrophy, Spinal
United States, Germany, Poland, United Kingdom
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRecruiting
NCT07174310Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Parkinson's Disease
United States, Australia, Austria, Brazil, Canada +12 more
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active Not Recruiting
NCT04524871Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Advanced Liver Cancers
United States, China, France, Israel, New Zealand +2 more
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruiting
NCT06084936Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Lymphoma
United States, Australia, Brazil, Canada, China +8 more
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruiting
NCT06790693Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Brazil, Canada +15 more

Previous page Next page